Bcal Diagnostics
- Short interest
- 0.00%
- −0.01 pp 30d
- as of 6 June 2025
- Reported shorts
- 304
- Shares on issue
- 365.968M
Bcal Diagnostics (BDX) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $2.5MM (source: ASX (Markit))vs $21.6K (FY25)
- ASX (Markit), as at 14 Oct 2026
- NPAT
- −$7.4MM (source: ASX (Markit))vs −$7.2M (FY25)
- ASX (Markit), as at 14 Oct 2026
- EPS (diluted)
- −$0.020T (source: Derived: trailing 12 months at year end)vs −$0.020 (FY25)
- Derived: trailing 12 months at year end, as at 14 Oct 2026
- Rev YoY
- n/mFY
- EPS YoY
- n/aTTM
- ASX (Markit)
- Derived: trailing 12 months at year end
Summary of Appendix 4E and Annual Report to shareholders, 28 Aug 2026
BCAL Diagnostics reported a 10% revenue decline to $2.55 million and a net loss of $7.37 million (1.8% wider) for FY2026. No dividend was declared. The company is transitioning from a single-product rollout to a broader early cancer detection platform, with Avantect® tests launched in Australia and BREASTESTplus™ 2 validation underway, but remains in a pre-revenue commercialisation phase with a $1.6 million cash balance.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 14 Oct 2026
- Gross margin
- 7.2%
- Operating margin
- −368.4%
- Net margin
- −289.2%
- FCF margin
- −259.6%
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- −30.0×
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- n/a
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: ASX (Markit) and Derived: trailing 12 months at year end, as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $2.5MM (source: ASX (Markit)) | $21.6K | $3.1MM (source: ASX (Markit)) | $2.9MM (source: ASX (Markit)) |
| Gross profit | $182.5KT (source: Derived: trailing 12 months at year end) | $21.6K | n/a | n/a |
| Operating income | −$9.4MT (source: Derived: trailing 12 months at year end) | −$10.0M | −$9.4M | −$7.9M |
| EBITDA | −$6.3MT (source: Derived: trailing 12 months at year end) | −$6.2M | −$5.8M | −$7.8M |
| EBIT | −$7.1MT (source: Derived: trailing 12 months at year end) | −$7.2M | −$6.4M | −$7.9M |
| Interest expense | $313.1KT (source: Derived: trailing 12 months at year end) | $45.7K | $42.2K | n/a |
| Pretax income | −$7.4MT (source: Derived: trailing 12 months at year end) | −$7.2M | −$6.4M | −$5.1M |
| Tax | $0T (source: Derived: trailing 12 months at year end) | $0 | $0 | $0 |
| NPAT | −$7.4MM (source: ASX (Markit)) | −$7.2M | −$6.4M | −$5.1M |
| Net interest income | −$312.0KT (source: Derived: trailing 12 months at year end) | $92.6K | −$48.5K | $46.1K |
| EPS basic | −$0.020T (source: Derived: trailing 12 months at year end) | −$0.020 | −$0.026 | −$0.024 |
| EPS diluted | −$0.020T (source: Derived: trailing 12 months at year end) | −$0.020 | −$0.026 | −$0.024 |
| Shares | n/a | 366.0M | 314.3M | 212.3M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Appendix 4E and Annual Report to shareholdersAnnual Results28 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report22 Apr 2026via asx_announcements
- BCAL Half Year Results Presentation December 2025Half Year Results18 Feb 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results17 Feb 2026via asx_announcements
- BCAL Webinar Review Half Year Results 18 February 11am AEDTHalf Year Results13 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report21 Jan 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Oct 2025via asx_announcements
- Appendix 4E and Annual ReportAnnual Results29 Aug 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jul 2025via asx_announcements
Showing 10 of 19 reports